Fletcher B.S., Kujubu D.A., Perrin D.M., Herschman H.R. (1992) Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J. Biol. Chem 267(7):4338-4344.
Funk C.D., Funk L.B., Kennedy M.E., Pong A.S., Fitzgerald G.A. (1991) Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J 5(9):2304-2312.
Niwa K., Haensel C., Ross M.E., Iadecola C. (2001) Cyclooxygenase-1 participates in selected vasodilator responses of the cerebral circulation. Circ. Res 88(6):600-608.
Smith W.L., Meade E.A., Dewitt D.L. (1994) Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann. NY. Acad. Sci 744:50-57.
Masferrer J.L., Zweifel B.S., Manning P.T. (1994) Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. USA 91(8):3228-3232.
Peskar B.M. (2001) Role of cyclooxygenase isoforms in gastric mucosal defence. J. Physiol. Paris 95(1-6):3-9.
Komhoff M., Grone H.J., Klein T., Seyberth H.W., Nusing R.M. (1997) Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: Implication for renal function. Am. J. Physiol 272(4 PART 2).
Seibert K., Zhang Y., Leahy K., Hauser S., Masferrer J., Isakson P. (1997) Distribution of COX-1 and COX-2 in normal and inflamed tissues. Adv. Exp. Med. Biol 400 A:167-170.
Khan K.N., Venturini C.M., Bunch R.T. (1998) Interspecies differences in renal localization of cyclooxygenase isoforms: Implications in nonsteroidal antiinflammatory drug-related nephrotoxicity. Toxicol. Pathol 26(5):612-620.
Crofford L.J. (1997) COX-1 and COX-2 tissue expression: Implications and predictions. J. Rheumatol 24 S(49):15-19.
Arakawa T., Higuchi K., Fukuda T., Fujiwara Y., Kobayashi K., Kuroki T. (1998) Prostaglandins in the stomach: An update. J. Clin. Gastroenterol 27 S(1).
Vane J.R., Bakhle Y.S., Botting R.M. (1998) Cyclooxygenases 1 and 2. Ann. Rev. Pharmacol. Toxicol 38:97-120.
Yucel-Lindberg T., Ahola H., Carlstedt-Duke J., Modeer T. (1999) Involvement of tyrosine kinases on cyclooxygenase expression and prostaglandin E2 production in human gingival fibroblasts stimulated with interleukin-1 beta and epidermal growth factor. Biochem. Biophys. Res. Commun 257(2):528-532.
Smith W.L., Dewitt D.L., Garavito R.M. (2000) Cyclooxygenases: Structural, cellular, and molecular biology. Ann. Rev. Biochem 69:145-182.
Crofford L.J., Wilder R.L., Ristimaki A.P. (1994) Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1β, phorbol ester, and corticosteroids. J. Clin. Invest 93(3):1095-1101.
Mifflin R.C., Saada J.I., Di Mari J.F., Adegboyega P.A., Valentich J.D., Powell D.W. (2002) Regulation of COX-2 expression in human intestinal myofibroblasts: Mechanisms of IL-1-mediated induction. Am. J. Physiol. Cell. Physiol 282(4).
Cao C., Matsumura K., Shirakawa N. (2001) Pyrogenic cytokines injected into the rat cerebral ventricle induce cyclooxygenase-2 in brain endothelial cells and also upregulate their receptors. Eur. J. Neurosci 13(9):1781-1790.
Samad T.A., Moore K.A., Sapirstein A. (2001) Interleukin-1β-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature , 6827; 410:471-475.
Lopez-Urrutia L., Alonso A., Bayon Y., Nieto M.L., Orduna A., Sanchez Crespo M. (2001) Brucella lipopolysaccharides induce cyclooxygenase-2 expression in monocytic cells. Biochem. Biophys. Res. Commun 289(2):372-375.
Devaux Y., Seguin C., Grosjean S. (2001) Lipopolysaccharide-induced increase of prostaglandin E(2) is mediated by inducible nitric oxide synthase activation of the constitutive cyclooxygenase and induction of membrane-associated prostaglandin E synthase. J. Immunol 167(7):3962-3971.
Futaki N., Takahashi S., Kitagawa T., Yamakawa Y., Tanaka M., Higuchi S. (1997) Selective inhibition of cyclooxygenase-2 by NS-398 in endotoxin shock rats in vivo. Inflamm. Res 46(12):496-502.
Goppelt-Struebe M., Beiche F. (1997) Cyclooxygenase-2 in the spinal cord: Localization and regulation after a peripheral inflammatory stimulus. Adv. Exp. Med. Biol 433:213-216.
Coffey R.J., Hawkey C.J., Damstrup L. (1997) Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc. Natl. Acad. Sci. USA 94(2):657-662.
Mitchell J.A., Evans T.W. (1998) Cyclooxygenase-2 as a therapeutic target. Inflamm. Res 47 S(2).
Cao Y., Prescott S.M. (2002) Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J. Cell. Physiol 190(3):279-286.
Chan G., Boyle J.O., Yang E.K. (1999) Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer. Res 59(5):991-994.
Peng J.P., Su C.Y., Chang H.C., Chai C.Y., Hung W.C. (2002) Overexpression of cyclooxygenase 2 in squamous cell carcinoma of the hypopharynx. Hum. Pathol 33(1):100-104.
Half E., Tang X.M., Gwyn K., Sahin A., Wathen K., Sinicrope F.A. (2002) Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62(6):1676-1681.
Brodie A.M., Lu Q., Long B.J. (2001) Aromatase and COX-2 expression in human breast cancers. J. Steroid. Biochem. Mol. Biol 79(1-5):41-47.
Yoshimatsu K., Altorki N.K., Golijanin D. (2001) Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin. Cancer Res 7(9):2669-2674.
Dannenberg A.J., Altorki N.K., Boyle J.O., Lin D.T., Subbaramaiah K. (2001) Inhibition of cyclooxygenase-2: An approach to preventing cancer of the upper aerodigestive tract. Ann. NY. Acad. Sci 952:109-115.
Taketo M.M. (1998) COX-2 and colon cancer. Inflamm. Res 47 S(2).
Maekawa M., Sugano K., Sano H. (1998) Increased expression of cyclooxygenase-2 to -1 in human colorectal cancers and adenomas, but not in hyperplastic polyps. Jpn. J. Clin. Oncol 28(7):421-426.
Niijima M., Yamaguchi T., Ishihara T. (2002) Immunohistochemical analysis and in situ hybridization of cyclooxygenase-2 expression in intraductal papillary-mucinous tumors of the pancreas. Cancer 94(5):1565-1573.
Specht M.C., Tucker O.N., Hocever M., Gonzalez D., Teng L., Fahey T.J. III (2002) Cyclooxygenase-2 expression in thyroid nodules. J. Clin. Endocrinol. Metab 87(1):358-363.
Lee L.M., Pan C.C., Cheng C.J., Chi C.W., Liu T.Y. (2001) Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Res 21 B(2):1291-1294.
Chan T.A. (2002) Nonsteroidal anti-inflammatory drugs, apoptosis and colon cancer chemoprevention. Lancet Oncol 3(3):166-174.
Lynch P.M. (2001) COX-2 inhibition in clinical cancer prevention. Oncology (Huntingt.) 15(3 SUPPL. 5):21-26.
Masferrer J. (2001) Approach to angiogenesis inhibition based on cyclooxygenase-2. Cancer J 7 S(3).
Leahy K.M., Koki A.T., Masferrer J.L. (2000) Role of cyclooxygenases in angiogenesis. Curr. Med. Chem 7(11):1163-1170.
Lukiw W.J., Bazan N.G. (1997) Cyclooxygenase 2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer neocortex. J. Neurosci. Res 50(6):937-945.
Cryer B. (2001) Mucosal defense and repair. Role of prostaglandins in the stomach and duodenum. Gastroenterol. Clin. North. Am 30(4):877-894.
Dewitt D.L. (1999) Cox-2-selective inhibitors: The new super aspirins. Mol. Pharmacol 55(4):625-631.
Needleman P., Turk J., Jakschik B.A., Morrison A.R., Lefkowith J.B. (1986) Arachidonic acid metabolism. Ann. Rev. Biochem 55:69-102.
Omini C., Moncada S., Vane J.R. (1977) The effects of prostacyclin (PGI2) on tissues which detect prostaglandins (PG'S). Prostaglandins 14(4):625-632.
Dogne J.M., De Leval X., Delarge J., David J.L., Masereel B. (2000) New trends in thromboxane and prostacyclin modulators. Curr. Med. Chem 7(6):609-628.
Vapaatalo H., Parantainen J. (1978) Prostaglandins; their biological and pharmacological role. Med. Biol 56(4):163-183.
Carsten M.E. (1974) Prostaglandins and oxytocin: Their effects on uterine smooth muscle. Prostaglandins 5(1):33-40.
Weber P.C. (1980) Renal prostaglandins, kidney function and essential hypertension. Contrib. Nephrol 23:83-92.
Granger J.P., Alexander B.T., Llinas M. (2002) Mechanisms of pressure natriuresis. Curr. Hypertens. Rep 4(2):152-159.
Tazawa R., Xu X.M., Wu K.K., Wang L.H. (1994) Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochem. Biophys. Res. Commun 203(1):190-199.
Kosaka T., Miyata A., Ihara H. (1994) Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur. J. Biochem 221(3):889-897.
Yokoyama C., Tanabe T. (1989) Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem. Biophys. Res. Commun 165(2):888-894.
Kraemer S.A., Meade E.A., Dewitt D.L. (1992) Prostaglandin endoperoxide synthase gene structure: Identification of the transcriptional start site and 5′-flanking regulatory sequences. Arch. Biochem. Biophys 293(2):391-400.
Herschman H.R. (1991) Primary response genes induced by growth factors and tumor promoters. Ann. Rev. Biochem 60:281-319.
Herschman H.R. (1994) Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer Metastasis Rev 13(3-4):241-256.
Kujubu D.A., Fletcher B.S., Varnum B.C., Lim R.W., Herschman H.R. (1991) TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem 266(20):12866-12872.
Shaw G., Kamen R. (1986) A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 46(5):659-667.
O'Banion M.K., Winn V.D., Young D.A. (1992) cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc. Natl. Acad. Sci. USA 89(11):4888-4892.
Shalom-Barak T., Quach J., Lotz M. (1998) Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-κB. J. Biol. Chem 273(42):27467-27473.
Imseis H.M., Zimmerman P.D., Samuels P., Kniss D.A. (1997) Tumour necrosis factor-alpha induces cyclo-oxygenase-2 gene expression in first trimester trophoblasts: Suppression by glucocorticoids and NSAIDs. Placenta 18(7):521-526.
Perkins D.J., Kniss D.A. (1997) Tumor necrosis factor-α promotes sustained cyclooxygenase-2 expression: Attenuation by dexamethasone and NSAIDs. Prostaglandins 54(4):727-743.
Bennett P.R., Moore G.E. (1991) Genetic conservation of cyclo-oxygenase. Prostaglandins 41(2):135-142.
Smith W.L., Garavito R.M., Dewitt D.L. (1996) Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J. Biol. Chem 271(52):33157-33160.
Otto J.C., Smith W.L. (1994) The orientation of prostaglandin endoperoxide synthases-1 and -2 in the endoplasmic reticulum. J. Biol. Chem 269(31):19868-19875.
Murakami M., Matsumoto R., Austen K.F., Arm J.P. (1994) Prostaglandin endoperoxide synthase-1 and -2 couple to different transmembrane stimuli to generate prostaglandin D2 in mouse bone marrow-derived mast cells. J. Biol. Chem 269(35):22269-22275.
Garavito R.M. (1996) The cyclooxygenase-2 structure: New drugs for an old target?. Nat. Struct. Biol 3(11):897-901.
Loll P.J., Picot D., Garavito R.M. (1995) The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat. Struct. Biol 2(8):637-643.
Luong C., Miller A., Barnett J., Chow J., Ramesha C., Browner M.F. (1996) Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat. Struct. Biol 3(11):927-933.
Iseki S. (1995) Immunocytochemical localization of cyclooxygenase-1 and cyclooxygenase-2 in the rat stomach. Histochem. J 27(4):323-328.
Harris R.C., McKanna J.A., Akai Y., Jacobson H.R., Dubois R.N., Breyer M.D. (1994) Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J. Clin. Invest 94(6):2504-2510.
Slater D., Allport V., Bennett P. (1998) Changes in the expression of the type-2 but not the type-1 cyclo-oxygenase enzyme in chorion-decidua with the onset of labour. Br. J. Obstet. Gynaecol 105(7):745-748.
Kurumbail R.G., Stevens A.M., Gierse J.K. (1996) Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384:644-648.
Service R.F. (1996) Closing in on a stomach-sparing aspirin substitute. Science 273:1660.
Whitehouse M.W. (1967) Evaluation of potential antirheumatic drugs in vitro using lymphocytes and epithelial cells. The selective action of indoxole, methyl glyoxal and chloroquine. J. Pharm. Pharmacol 19(9):590-595.
Kaiser D.G., Glenn E.M., Johnson R.H., Johnston R.L. (1967) Correlation of serum indoxole [2,3-bis(p-methoxyphenyl)-indole] levels with biologic activity. J. Pharmacol. Exp. Ther 155(1):174-180.
Higuchi S., Osada Y., Shioiri Y. (1984) Anti-inflammatory activity of a non-steroidal anti-inflammatory agent, oxaprozin, in experimental models. Nippon Yakurigaku Zasshi 83(5):383-394.
Tsuji K., Nakamura K., Konishi N. (1997) Studies on anti-inflammatory agents. IV. Synthesis and pharmacological properties of 1,5-diarylpyrazoles and related derivatives. Chem. Pharm. Bull. (Tokyo) 45(6):987-999.
Penning T.D., Talley J.J., Bertenshaw S.R. (1997) Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benze nesulfonamide (SC-58635, celecoxib). J. Med. Chem 40(9):1347-1365.
Seibert K., Zhang Y., Leahy K. (1994) Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc. Natl. Acad. Sci. USA 91(25):12013-12017.
Bensen W.G., Zhao S.Z., Burke T.A. (2000) Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J. Rheumatol 27(8):1876-1883.
Silverstein F.E., Faich G., Goldstein J.L. (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284(10):1247-1255.
Mckenna F., Borenstein D., Wendt H., Wallemark C., Lefkowith J.B., Geis G.S. (2001) Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand. J. Rheumatol 30(1):11-18.
Gimbel J.S., Brugger A., Zhao W., Verburg K.M., Geis G.S. (2001) Efficacy and tolerability of celecoxib versus hydrocodone/acetaminophen in the treatment of pain after ambulatory orthopedic surgery in adults. Clin. Ther 23:2228-2241.
North G.L. (2001) Celecoxib as adjunctive therapy for treatment of colorectal cancer. Ann. Pharmacother 35(12):1638-1643.
Riendeau D., Percival M.D., Brideau C. (2001) Etoricoxib (MK-0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J. Pharmacol. Exp. Ther 296:558-566.
Matheson A.J., Figgitt D.P. (2001) Rofecoxib: A review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. Drugs 61(6):665-833.
Detora L.M., Krupa D., Bolognese J., Sperling R.S., Ehrich E.W. (2001) Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors. J. Rheumatol 28(11):2494-2503.
Camu F., Beecher T., Recker D.P., Verburg K.M. (2002) Valdecoxib, a COX-2-specific inhibitor, is an efficacious, opioidsparing analgesic in patients undergoing hip arthroplasty. Am. J. Ther 9(1):43-51.
Fricke J., Varkalis J., Zwillich S. (2002) Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery. Am. J. Ther 9(2):89-97.
Talley J.J., Brown D.L., Carter J.S. (2000) 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: A potent and selective inhibitor of COX-2. J. Med. Chem 43(5):775-777.
Harris S.I., Kuss M., Hubbard R.C., Goldstein J.L. (2001) Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo. Clin. Ther 23(9):1422-1428.
Lim H., Paria B.C., Das S.K. (1997) Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 91(2):197-208.
Rocca B., Spain L.M., Ciabattoni G., Patrono C., Fitzgerald G.A. (1999) Differential expression and regulation of cyclooxygenase isozymes in thymic stromal cells. J. Immunol 162(8):4589-4597.
Rocca B., Spain L.M., Pure E., Langenbach R., Patrono C., Fitzgerald G.A. (1999) Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. J. Clin. Invest 103(10):1469-1477.
Harris R.C., Breyer M.D. (2001) Physiological regulation of cyclooxygenase-2 in the kidney. Am. J. Physiol. Renal. Physiol 281(1).
Robertson R.P. (1998) Dominance of cyclooxygenase-2 in the regulation of pancreatic islet prostaglandin synthesis. Diabetes 47(9):1379-1383.
Breder C.D., Dewitt D., Kraig R.P. (1995) Characterization of inducible cyclooxygenase in rat brain. J. Comp. Neurol 355(2):296-315.
Nakao S., Ogata Y., Shimizusasaki E., Yamazaki M., Furuyama S., Sugiya H. (2000) Activation of NFκB is necessary for IL-1β-induced cyclooxygenase-2 (COX-2) expression in human gingival fibroblasts. Mol. Cell. Biochem 209(1-2):113-118.
Gorgoni B., Caivano M., Arizmendi C., Poli V. (2001) The transcription factor C/EBPβ is essential for inducible expression of the cox-2 gene in macrophages but not in fibroblasts. J. Biol. Chem 276(44):40769-40777.
Mestre J.R., Mackrell P.J., Rivadeneira D.E., Stapleton P.P., Tanabe T., Daly J.M. (2001) Redundancy in the signaling pathways and promoter elements regulating cyclooxygenase-2 gene expression in endotoxin-treated macrophage/monocytic cells. J. Biol. Chem 276(6):3977-3982.
Gilroy D.W., Tomlinson A., Willoughby D.A. (1998) Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation. Eur. J. Pharmacol 355(2-3):211-217.
